home / stock / tcon / tcon news


TCON News and Press, TRACON Pharmaceuticals Inc. From 04/03/19

Stock Information

Company Name: TRACON Pharmaceuticals Inc.
Stock Symbol: TCON
Market: OTC
Website: traconpharma.com

Menu

TCON TCON Quote TCON Short TCON News TCON Articles TCON Message Board
Get TCON Alerts

News, Short Squeeze, Breakout and More Instantly...

TCON - GME and ADXS among premarket losers

Fusion Connect (NASDAQ: FSNN ) -82%  as audit problems prompt Chapter 11 analyst warning. More news on: Fusion Connect, Inc., Advaxis, Inc., AVEO Pharmaceuticals, Inc., Stocks on the move, Read more ...

TCON - TRACON Pharmaceuticals Announces TRC105, TRC253 and TRC102 Data Presentations at Upcoming AACR Annual Meeting

SAN DIEGO, March 27, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and, through our license to Santen Pharmaceutical Co. Ltd., wet age-relat...

TCON - AVGO, BDSI and NVLN among premarket gainers

Achieve Life Sciences (NASDAQ: ACHV ) +77%  on advancement of cytisinicline. More news on: Achieve Life Sciences, Inc., Soleno Therapeutics, Inc., MDC Partners Inc., Stocks on the move, Read more ...

TCON - TRACON Pharmaceuticals (TCON) CEO Charles Theuer on Q4 2018 Results - Earnings Call Transcript

TRACON Pharmaceuticals Inc. (NASDAQ:TCON) Q4 2018 Earnings Conference Call February 28, 2019 4:30 PM ET Company Participants Charles Theuer - President and Chief Executive Officer Scott Brown - Director, Controller Conference Call Participants Maury Raycroft - Jefferies J...

TCON - Tracon beats by $0.26

Tracon (NASDAQ: TCON ): Q4 GAAP EPS of -$0.26 beats by $0.26. More news on: Tracon Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , Read more ...

TCON - TRACON to Report Fourth Quarter and Full Year 2018 Company Highlights and Financial Results on February 28, 2019

SAN DIEGO, Feb. 21, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration, announced today that it will rep...

TCON - Week In Review: China Green Lights Nasdaq-Style Exchange For Young Companies

Government and Regulatory China has given the green light to a new registration-based Shanghai stock exchange aimed at high tech companies that, apparently, will be less regulated than other China exchanges. The new exchange is described as resembling NASDAQ with its dealer-to-dealer prici...

TCON - TRACON Pharmaceuticals Announces Positive Data from Ongoing Phase 1b/2 Trial of TRC105 in Hepatocellular Carcinoma

Three Confirmed Partial Responses (20%) by RECIST and > 50% Reductions of Alpha Fetoprotein in Half of Patients Treated to Date with Combination of TRC105 and Nexavar®   Data Presented at ASCO 2019 Gastrointestinal Cancers Symposium SAN DIEGO, Jan. 22, 2019 (GLOBE NEWS...

Previous 10 Next 10